Efficacy of teriparatide compared with risedronate on FRAX(R)-defined major osteoporotic fractures: results of the VERO clinical trial

J.J. Body, F. Marine, D.L. Kendler, C.A.F. Zerbini, P. Lopez-Romero, R. Moricke, E. Casado, A. Fahrleitner-Pammer, J.J. Stepan, E. Lespessailles, S. Minisola, P. Geusens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1935-1942
Number of pages8
JournalOsteoporosis International
Volume31
Issue number10
DOIs
Publication statusPublished - 1 Oct 2020

Keywords

  • abaloparatide
  • alendronate
  • bisphosphonates
  • fractures
  • frax(r)
  • osteoporosis
  • postmenopausal women
  • probability
  • risedronate
  • risk
  • teriparatide
  • vertebral fractures
  • Risedronate
  • FRAX(R)
  • RISK
  • Bisphosphonates
  • ALENDRONATE
  • Osteoporosis
  • PROBABILITY
  • Fractures
  • ABALOPARATIDE
  • VERTEBRAL FRACTURES
  • POSTMENOPAUSAL WOMEN
  • Teriparatide

Cite this